- Question from samita: What do you most HOPE to hear about at next year's ASCO?
- Answers - Beth Baughman DuPree, M.D., F.A.C.S. That I don't have to be a breast surgeon anymore!
- Nicholas Robert, M.D. There is something we haven't talked about tonight, which is the use of intravenous bisphosphonates. There was some exciting work from Austria that suggests the use of intravenous bisphosphonates, especially the use of Zometa (chemical name: zoledronic acid), could reduce the risk for recurrence of metastatic disease. There is a much larger study addressing this same question that hopefully we will hear about at next ASCO to provide more information on the potential benefit of intravenous bisphosphonates in early breast cancer. We know that the use of bisphosphonates is important to preserve bone health in postmenopausal women; it would be very exciting to learn that it can also reduce the risk of breast cancer recurrence.
On Wednesday, June 24, 2009, our Ask-the-Expert Online Conference was called Updates from the ASCO Annual Meeting. Nick Robert, M.D. and Beth Baughman Dupree, M.D., F.A.C.S. answered your questions about the newest findings on risk, screening, treatment, and more.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.